SPARTA Biodiscovery is a company commercializing the SPARTA® technology, which enables the accurate chemical analysis of nanoparticles in nanoformulations for next-generation therapeutics.

SPARTA Biodiscovery

Biontis GmbH develops and produces components and complete systems for innovative and cost-effective analytics.

Biontis GmbH

SPARTA Biodiscovery is a brand-new spin-out company from Imperial College London developing and commercialising the SPARTA® technology. SPARTA® (Single Particle Automated Raman Trapping Analysis) is a breakthrough analytical technology for automated, label-free comprehensive characterisation of nanoformulations. SPARTA® is available through our service offering and in the near future as a benchtop instrument.

We welcome two great new team members this month! Ashkan Roozbeh has joined us as Senior Optical Engineer and Callum Macdonald as Software Engineer! #team!

What a start to the new year! Our co-founder Molly Stevens has been awarded a Damehood in the New Year Honours! https://lnkd.in/eVcPQqAg 
Congratulations Professor Dame Molly Stevens!

How can we use #nanotechnology to tackle antibiotic resistance? One approach is to use nanoparticles as reaction chambers, or #nanoreactors, to convert products released by bacteria into bactericidal agents to locally kill bacteria cells.
Michael Potter, PhD, Molly Stevens and team carefully designed semi-permeable nanoreactors loaded with antimicrobial enzymes to convert glucose into hypochlorite, a potent antimicrobial.
#SPARTA was used to demonstrate the semi-permeability of their nanoreactors on the single particle scale, as well as for detailed characterisation of the carrier chemistry.
Read more here! https://lnkd.in/etF2t7B8

Loading your small molecule API into a lipid delivery system is a challenge.  How does your molecule’s chemistry affect how it loads into #nanoparticles?
#SPARTA looks at the chemical profile of individual nanoparticles, in a rapid, automated, label-free manner, to tell you precisely how heterogeneously your cargoes are loading.
Check out how this has been shown in liposomes and polymer vesicles, including for the commercial #nanoformulation Doxil. #analytics

https://lnkd.in/gjRhJN_8

You spent years finding the right target. Do you have the optimal vector? 

LNP's as a vector have emerged as a leading platform. But, what gives you confidence your proprietary lipid composition or targeting ligand density is well known or characterized? 

#SPARTA can provide unparalleled insight into your formulation's composition in a rapid and automated format down to the single particle level. #nanoformulations #analytics 
https://lnkd.in/epgdJtzG

Join our CEO Jelle Penders speaking today at the 20th Anniversary #bioProcessUK conference of the BioIndustry Association (BIA) at the Next Generation Analytics session to learn how #SPARTA is Enabling #Nanoformulations for Next-Generation Therapeutics!

How well do you know your #nanomedicine? SPARTA looks the individual particle level in an automated and label-free way with minimal sample prep. Learn more today about how #SPARTA can bring you valuable insights!
https://lnkd.in/eVV2VS_n #nanoformulations #analytics

Our co-founder Molly Stevens was recently interviewed by Drug Discovery World! Read the article to find out more about her career highlights and how SPARTA fulfills an unmet need in drug delivery platform development. #nanoformulations #analytics

Metric
Company Name	SPARTA Biodiscovery	Biontis GmbH
Symbol
MSH ID	COM:SPARTABIODISCOVERY	DE:BIONTIS
Market	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	GB	DE
Stage	Seed	Venture Round
Employee Count	6	3
Website	spartabiodiscovery.com	biontis.de
LinkedIn	sparta-biodiscovery
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	4.27M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SPARTABIODISCOVERY

SPARTA Biodiscovery

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue